Yannick Hoffmann is Global Business Process Owner / Business System Owner Shopfloor Serialization at Roche. His specialities are Project and Test Management, Serialization & Track and Trace, Warehouse Management.

Klaus Egner studied physics at the TU Darmstadt. After graduating with a degree in engineering, he trained
technical business economist while working. Since 1998, Mr. Egner has been working for Merck KGaA, initially in the Automation division, where he was responsible for laboratories and in the field of chemistry. In 2004, his area of responsibility changed to the pharmaceuticals division with different areas of support (MES, production and packaging solids). In 2011, the implementation of Track & Trace in the packaging sector became hishis main focus. Since Aug. 2019, he has been responsible for Track & Trace in packaging in a global function at Merck Healthcare KGaA.

Being a mathematician and chemical engineer by profession Stefan is involved in pharmaceutical serialization since its early days in 2008 and renowned as one of the fathers of the European ‘Point-of-Dispense Verification’ model that ensures patients’ access to safe medicines.
For more than seven years Stefan worked as a delegate consultant for the European Federation of Pharmaceutical Industries and Associations (EFPIA) where he contributed to the successful verification pilot in Sweden in 2009 / 2010 and played a key role in the design and development of the European Medicines Verification System (EMVS) that constitutes a key component in the implementation of the EU Falsified Medicines Directive (FMD).
Once having returned from Brussels Stefan led Bayer’s activities to implement the Brazilian Track&Trace requirements in 2014 and 2015 before his focus shifted back to the roots as the responsible program manager for the timely FMD readiness of Bayer’s Pharmaceuticals and Consumer Health divisions by February 2019. Currently, he manages Bayer’s rollout of Track&Trace for Brazil that was restarted by ANVISA in 2020.
Beyond his project assignments Stefan Artlich engages on a strategic level for supply chain improvements ensuring patients’ safety and uninterrupted access to medicines. As an example, he serves since 2016 as an elected member of the GS1 Healthcare Leadership Team that steers GS1 Healthcare’s activities for the integration of GS1 standards into the supply chain processes of the healthcare sector in order to drive patient safety and supply chain efficiency improvements not only in the private but as well in the public sector.

Robert Potts is Director, International Quality at Vertex Pharmaceuticals for 9 + years. There he is responsible for the international expansion and product distribution internationally. He has over 14 years experience in the pharmaceutical industry. He has founded knowledge in GDP, GMP, GCP, GPVP.

Carolin Dose is Process & Analytics Analyst at Global Supply Management at Bayer. She has founded knowledge in the field of supply chain and serialization.

Michael Kinsella is Program Director Serialisation & Packaging at Servier. In his position he is responsible for managing Servier’s Global Serialization program delivery with transverse cooperate and international teams and ensuring global on-time program delivery for Europe, Gulf region, Russia (Pilot Working group member), S. Korea, US, China, India, Pakistan, Saudi Arabia and Egypt (National pilot member).

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Our pursuit is progress for people everywhere. That's why we take a closer look at things, ask questions and think ahead. We've been around for 350 years, yet our majority owners are still the descendants of Friedrich Jacob Merck, the man who founded our company in Darmstadt, Germany in 1668. Since then, we have become a truly global company, with 50,000 employees in 66 countries working on breakthrough solutions and technologies. In 2016, we invested a total of € 2.0 billion in research and development. We are Merck. The only exceptions are the United States and Canada. Here we operate as EMD Serono in the Biopharma business, as MilliporeSigma in the Life Science business, and as EMD Performance Materials in the materials business.

Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time. A growing and aging world population requires an adequate supply of food and improved medical care. With life expectancy continuing to rise, we improve quality of life for a growing population by focusing our research and development activities on preventing, alleviating and treating diseases. We are also making an important contribution to providing a reliable supply of high-quality food, feed and plant-based raw materials.

We’re focused on discovering, developing and bringing innovative medicines to people with serious diseases so they can lead better lives. In pursuit of this mission, we are advancing a robust research pipeline that includes potentially transformative treatments for cystic fibrosis, pain, sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, APOL1-mediated kidney disease, Duchenne muscular dystrophy, type 1 diabetes and more.

We are an international pharmaceutical company governed by a non-profit foundation, with our headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.176 billion euros in 2018, we employ 22.000 people worldwide. Entirely independent, we reinvest 25% of our turnover (excluding generic drugs) in research and development and use all our profits for development. Corporate growth is driven by our constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric disease, cancer and diabetes, as well as by our activities in high-quality generic drugs. Currently, we have 33 drug candidates including 22 new molecular entities at various stages of clinical development. Our priorities are pathologies with high medical needs within our areas of expertise.